These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
803 related articles for article (PubMed ID: 27393509)
1. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509 [TBL] [Abstract][Full Text] [Related]
2. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662 [TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266 [TBL] [Abstract][Full Text] [Related]
4. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy. Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449 [TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971 [TBL] [Abstract][Full Text] [Related]
6. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003 [TBL] [Abstract][Full Text] [Related]
7. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer. Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393 [TBL] [Abstract][Full Text] [Related]
8. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578 [TBL] [Abstract][Full Text] [Related]
9. Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition. Kwon MJ; Rho YS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Kim ES; Park B; Hong M; Min KW Hum Pathol; 2018 Oct; 80():28-39. PubMed ID: 29634978 [TBL] [Abstract][Full Text] [Related]
10. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. Song Z; Yu X; Zhang Y Lung Cancer; 2016 Sep; 99():166-71. PubMed ID: 27565935 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915 [TBL] [Abstract][Full Text] [Related]
12. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. Song Z; Yu X; Cheng G; Zhang Y J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566 [TBL] [Abstract][Full Text] [Related]
13. Expression of PD-L1, cancer stem cell and epithelial-mesenchymal transition phenotype in non-small cell lung cancer. Koh YW; Han JH; Haam S Pathology; 2021 Feb; 53(2):239-246. PubMed ID: 33036771 [TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study. Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075 [TBL] [Abstract][Full Text] [Related]
16. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500 [TBL] [Abstract][Full Text] [Related]
18. Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. Lee SE; Kim YJ; Sung M; Lee MS; Han J; Kim HK; Choi YL Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561631 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031 [TBL] [Abstract][Full Text] [Related]
20. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor. Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]